Kyle LaHucik

Pfiz­er is end­ing the de­vel­op­ment and com­mer­cial­iza­tion of its he­mo­phil­ia B gene ther­a­py Be­qvez, the com­pa­ny con­firmed in an emailed state­ment to End­points News. …

Con­cen­tra Bio­sciences, the shell com­pa­ny from Tang Cap­i­tal that tries to buy out strug­gling biotechs, has found an­oth­er tar­get, this time try­ing to throw a

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

Ko­jin Ther­a­peu­tics, a start­up at­tempt­ing to de­vel­op new treat­ments us­ing pro­grammed cell death, left last month’s JP Mor­gan Health­care Con­fer­ence in a bind. It need­ed

In a sur­prise move Thurs­day, Neumo­ra re­made its ex­ec­u­tive team and brought back its for­mer CEO, fol­low­ing last month’s fail­ure of the brain health biotech’

Aard­vark Ther­a­peu­tics, a biotech look­ing to ad­dress hunger rather than ap­petite for meta­bol­ic dis­eases, will go pub­lic on Thurs­day with a $94 mil­lion de­but on

Newleos Ther­a­peu­tics emerged Thurs­day with $93.5 mil­lion and a bun­dle of oral small mol­e­cules that it li­censed from Roche, fur­ther demon­strat­ing that the phar­ma-to-start­up pipeline